Literature DB >> 31408513

Controlled substance diversion in health systems: A failure modes and effects analysis for prevention.

Karen Nolan1, Andrew R Zullo2, Elliott Bosco3, Christine Marchese4, Christine Berard-Collins5.   

Abstract

PURPOSE: The purpose of this study was to demonstrate the utility of failure modes and effects analysis (FMEA) for systematically identifying potential sources of controlled substance diversion and developing solutions in an academic health system.
METHODS: The FMEA was conducted by an 18-member cross-functional team from the department of pharmacy. The team developed scoring criteria specifically for controlled substance diversion, outlined the controlled substance processes from procurement to administration or disposal, and identified ways in which each step of the medication supply process might fail (failure modes) and result in diversion of controlled substances. Failure modes with a vulnerability score of 48 or 64 were considered highest risk and were immediately intervened on by the FMEA team.
RESULTS: The FMEA outlined a total of 10 major steps and 30 substeps in the controlled substance supply process. From this, 103 potential failure modes were identified, with 24 modes (23%) receiving a vulnerability score of 48 or 64. Development of specific reports addressed 15 failure modes, while 9 involved pharmacy workflow alterations. Notable reports included controlled substance activity under temporary patients and discrepancy trends by user, medication, and patient care area. Notable workflow alterations included expanded use of cameras in high-risk areas and additional verification checks.
CONCLUSION: FMEA allowed for systematic identification of controlled substance diversion opportunities, prioritization by level of vulnerability, and the development of targeted strategies to reduce risk of diversion. © American Society of Health-System Pharmacists 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  analgesics; healthcare failure mode and effect analysis; medication systems; opioid; pharmaceutical services; prescription drug diversion

Mesh:

Year:  2019        PMID: 31408513      PMCID: PMC7170724          DOI: 10.1093/ajhp/zxz116

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  11 in total

1.  Development of a computerized monitoring program to identify narcotic diversion in a pediatric anesthesia practice.

Authors:  B Randall Brenn; Margaret A Kim; Elora Hilmas
Journal:  Am J Health Syst Pharm       Date:  2015-08-15       Impact factor: 2.637

2.  Compliance with recommendations for prevention and detection of controlled-substance diversion in hospitals.

Authors:  Steven R McClure; Brian C O'Neal; Dennis Grauer; Rick J Couldry; Allison R King
Journal:  Am J Health Syst Pharm       Date:  2011-04-15       Impact factor: 2.637

Review 3.  ASHP Guidelines on Preventing Diversion of Controlled Substances.

Authors:  Philip W Brummond; David F Chen; William W Churchill; John S Clark; Kevin R Dillon; Doina Dumitru; Lynn Eschenbacher; Toni Fera; Christopher R Fortier; Kristine K Gullickson; Kristen Jurakovich; Stan Kent; Jennifer Keonavong; Christine Marchese; Tricia Meyer; Lee B Murdaugh; Richard K Ogden; Brian C O'Neal; Steve Rough; Rafael Saenz; Jacob S Smith
Journal:  Am J Health Syst Pharm       Date:  2017-01-04       Impact factor: 2.637

4.  Preventing large-scale controlled substance diversion from within the pharmacy.

Authors:  Emory S Martin; Steven H Dzierba; David M Jones
Journal:  Hosp Pharm       Date:  2013-05

5.  Three kinds of proactive risk analyses for health care.

Authors:  Garill Coles; Becky Fuller; Kathleen Nordquist; Steve Weissenberger; Leann Anderson; Brooke DuBois
Journal:  Jt Comm J Qual Patient Saf       Date:  2010-08

6.  Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention.

Authors:  Keith H Berge; Kevin R Dillon; Karen M Sikkink; Timothy K Taylor; William L Lanier
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

7.  The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013.

Authors:  Curtis S Florence; Chao Zhou; Feijun Luo; Likang Xu
Journal:  Med Care       Date:  2016-10       Impact factor: 2.983

8.  Identifying and correcting communication failures among health professionals working in the Emergency Department.

Authors:  Annamaria Bagnasco; Barbara Tubino; Emanuela Piccotti; Francesca Rosa; Giuseppe Aleo; Pasquale Di Pietro; Loredana Sasso; Laura Gambino; Donatella Passalacqua
Journal:  Int Emerg Nurs       Date:  2012-12-01       Impact factor: 2.142

9.  Design of a safer approach to intravenous drug infusions: failure mode effects analysis.

Authors:  M Apkon; J Leonard; L Probst; L DeLizio; R Vitale
Journal:  Qual Saf Health Care       Date:  2004-08

Review 10.  Addiction and substance abuse in anesthesiology.

Authors:  Ethan O Bryson; Jeffrey H Silverstein
Journal:  Anesthesiology       Date:  2008-11       Impact factor: 7.892

View more
  4 in total

1.  A Continuous Observation Workflow Time Study to Assess Intravenous Push Waste.

Authors:  John Hertig; Kaitlyn Jarrell; Prachi Arora; Jonell Nwabueze; Charlotte Moureaud; Daniel D Degnan; Tate Trujillo
Journal:  Hosp Pharm       Date:  2020-06-02

2.  Impact of failure mode and effects analysis-based emergency management on the effectiveness of craniocerebral injury treatment.

Authors:  Xiao-Lan Shao; Ya-Zhou Wang; Xiong-Hui Chen; Wen-Juan Ding
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

Review 3.  Controlled Substance Waste: Concerns, Controversies, Solutions.

Authors:  Frank Breve; Jo Ann K LeQuang; Lisa Batastini
Journal:  Cureus       Date:  2022-02-24

4.  Vulnerabilities for Drug Diversion in the Handling, Data Entry, and Verification Tasks of 2 Inpatient Hospital Pharmacies: Clinical Observations and Healthcare Failure Mode and Effect Analysis.

Authors:  Maaike de Vries; Mark Fan; Dorothy Tscheng; Michael Hamilton; Patricia Trbovich
Journal:  J Patient Saf       Date:  2022-01-01       Impact factor: 2.844

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.